Biopharma company Keros' Q3 net loss narrows on Takeda license revenue

Keros Therapeutics

05/11/2025 21:12

Overview

Keros Q3 net loss narrows to $7.3 mln from $53 mln, largely due to Takeda license revenue

Company plans to return $375 mln of excess capital to stockholders

Research and development expenses decrease as Takeda assumes elritercept costs

Outlook

Company expects cash to fund operations into first half of 2028

Takeda plans Phase 3 trial for elritercept in myelodysplastic syndromes

Keros advancing Phase 2 trial for KER-065 in Duchenne muscular dystrophy

Result Drivers

TAKEDA LICENSE REVENUE - Revenue from license agreement with Takeda significantly reduced net loss

R&D EXPENSES DECREASE - Transition of elritercept-related R&D expenses to Takeda lowered costs

ADMIN EXPENSES INCREASE - External costs increased general and administrative expenses despite reduced headcount

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$7.28 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Keros Therapeutics Inc is $22.50, about 30.9% above its November 4 closing price of $15.55

Press Release: ID:nGNX8Gztlt

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)